JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Waly N.E. | |
| dc.contributor.author | Refaiy A. | |
| dc.contributor.author | Aborehab N.M. | |
| dc.contributor.other | Department of Physiology | |
| dc.contributor.other | Faculty of Medicine | |
| dc.contributor.other | Helwan University | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | 11795 | |
| dc.contributor.other | Egypt; Department of Pathology Faculty of Medicine | |
| dc.contributor.other | Assiut University | |
| dc.contributor.other | Assiut | |
| dc.contributor.other | 71515 | |
| dc.contributor.other | Egypt; Department of Biochemistry | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | MSA University | |
| dc.contributor.other | Giza | |
| dc.contributor.other | 11787 | |
| dc.contributor.other | Egypt | |
| dc.date.accessioned | 2020-01-09T20:41:22Z | |
| dc.date.available | 2020-01-09T20:41:22Z | |
| dc.date.issued | 2017 | |
| dc.identifier.issn | 9284680 | |
| dc.identifier.other | https://doi.org/10.1016/j.pathophys.2017.02.005 | |
| dc.identifier.other | PubMed ID : | |
| dc.identifier.uri | https://t.ly/kN7n3 | |
| dc.description | Scopus | |
| dc.description.abstract | Objective Osteoarthritis (OA) is a complex disease of the whole joint. Glucosamine (GlcN) treatment may have a chondroprotective effect on OA. We investigated the mechanism of action of glucosamine treatment through interleukin-10 (Il-10) and transforming growth factor ?-1 (TGF ?-1). Methods Thirty male albino rats were used. A single intraarticular (i.a.) injection of 2�mg of Monosodium Iodoacetate (MIA) was injected into the knee joint of anesthetized rats. GlcN (50 or 100�mg/kg/day, p.o. for 2 month) was administered orally. Serum levels of Il-10 and TGF-?1 were determined by ELISA. Histopathological changes in treated and control joints were examined using hematoxylin-eosin (H & E) staining. Results The mean serum level of IL-10 significantly decreased in the OA group compared to control group (P value�<�0.0001). On the other hand, mean serum level of IL-10 significantly increased in GlcN treated groups when compared to the OA group (P value�<�0.0001). Serum level of TGF ?-1 was significantly elevated in OA group compared to control group (P value�<�0.0001). On the other hand, the mean serum level of TGF ?-1 was significantly decreased in the GlcN treated groups when compared to the OA group (P value�<�0.0001). Histopathological evaluation of GlcN treated groups showed different grades of healing, according to Osteoarthritis Research Society International (OARSI) grading system. Conclusion Our results showed that IL-10 and TGF-?1 possibly mediate GlcN chondroprotective effects in OA. Both serum biomarkers can be useful in the follow-up of articular cartilage damage in clinical settings. � 2017 Elsevier B.V. | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=24001&tip=sid&clean=0 | |
| dc.language.iso | English | en_US |
| dc.publisher | Elsevier B.V. | en_US |
| dc.relation.ispartofseries | Pathophysiology | |
| dc.relation.ispartofseries | 24 | |
| dc.subject | Glucosamine | en_US |
| dc.subject | IL-10�TGF-? | en_US |
| dc.subject | Osteoarthritis | en_US |
| dc.subject | biological marker | en_US |
| dc.subject | glucosamine | en_US |
| dc.subject | interleukin 10 | en_US |
| dc.subject | transforming growth factor beta | en_US |
| dc.subject | animal experiment | en_US |
| dc.subject | animal model | en_US |
| dc.subject | Article | en_US |
| dc.subject | chondroprotection | en_US |
| dc.subject | controlled study | en_US |
| dc.subject | drug mechanism | en_US |
| dc.subject | enzyme linked immunosorbent assay | en_US |
| dc.subject | experimental osteoarthritis | en_US |
| dc.subject | healing | en_US |
| dc.subject | histopathology | en_US |
| dc.subject | male | en_US |
| dc.subject | nonhuman | en_US |
| dc.subject | protein blood level | en_US |
| dc.subject | rat | en_US |
| dc.title | IL-10 and TGF-?: Roles in chondroprotective effects of Glucosamine in experimental Osteoarthritis? | en_US |
| dc.type | Article | en_US |
| dcterms.isReferencedBy | Zhang, W., Ouyang, H., Dass, C.R., Xu, J., Current research on pharmacologic and regenerative therapies for osteoarthritis (2016) Bone. Res., 4, p. 15040; Hootman, J.M., Helmick, C.G., Projections of US prevalence of arthritis and associated activity limitations (2006) Arthritis Rheum., 54 (1), pp. 226-229; Berenbaum, F., Osteoarthritis year 2010 in review: pharmacological therapies (2011) Osteoarthr. Cartil., 19 (4), pp. 361-365; Hawker, G.A., Mian, S., Bednis, K., Stanaitis, I., Osteoarthritis year 2010 in review: non-pharmacologic therapy (2011) Osteoarthr. Cartil., 19 (4), pp. 366-374; Aghazadeh-Habashi, A., Kohan, M.H., Asghar, W., Jamali, F., Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis (2014) J. Pharm. Sci., 103 (2), pp. 760-767; Gibson, M., Li, H., Coburn, J., Moroni, L., Nahas, Z., Bingham, C., 3rd, et al: intra-articular delivery of glucosamine for treatment of experimental osteoarthritis created by a medial meniscectomy in a rat model (2014) J. Orthop. Res., 32 (2), pp. 302-309; Black, C., Clar, C., Henderson, R., MacEachern, C., McNamee, P., Quayyum, Z., The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation (2009) Health Technol. Assess., 13 (52), pp. 1-148; Bruyere, O., Reginster, J.Y., Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis (2007) Drugs Aging, 24 (7), pp. 573-580; Alekseeva, L.I., Sharapova, E.P., Kashevarova, N.G., Taskina, E.A., Anikin, S.G., Korotkova, T.A., [Use of ARTRA MSM FORTE in patients with knee osteoarthritis: results of a randomized open-label comparative study of the efficacy and tolerability of the drug] (2015) Ter. Arkh., 87 (12), pp. 49-54; Matsuno, H., Nakamura, H., Katayama, K., Hayashi, S., Kano, S., Yudoh, K., Effects of an oral administration of glucosamine-chondroitin-quercetin glucoside on the synovial fluid properties in patients with osteoarthritis and rheumatoid arthritis (2009) Biosci. Biotechnol. Biochem., 73 (2), pp. 288-292; Nakasone, Y., Watabe, K., Watanabe, K., Tomonaga, A., Nagaoka, I., Yamamoto, T., Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study (2011) Exp. Ther. Med., 2 (5), pp. 893-899; Grover, A.K., Samson, S.E., Benefits of antioxidant supplements for knee osteoarthritis: rationale and reality (2016) Nutr. J., 15, p. 1; Henrotin, Y., Marty, M., Mobasheri, A., What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? (2014) Maturitas, 78 (3), pp. 184-187; Fenton, J.I., Chlebek-Brown, K.A., Peters, T.L., Caron, J.P., Orth, M.W., Glucosamine HCl reduces equine articular cartilage degradation in explant culture (2000) Osteoarthr. Cartil., 8 (4), pp. 258-265; Gouze, J.N., Bordji, K., Gulberti, S., Terlain, B., Netter, P., Magdalou, J., Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes (2001) Arthritis Rheum., 44 (2), pp. 351-360; Naito, K., Matsui, Y., Maeda, K., Tanaka, K., Evaluation of the validity of the Autism Spectrum Quotient (AQ) in differentiating high-functioning autistic spectrum disorder from schizophrenia (2010) Kobe J. Med. Sci., 56 (3), pp. E116-24; Hulejova, H., Baresova, V., Klezl, Z., Polanska, M., Adam, M., Senolt, L., Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone (2007) Cytokine, 38 (3), pp. 151-156; Jung, Y.K., Kim, G.W., Park, H.R., Lee, E.J., Choi, J.Y., Beier, F., Role of interleukin-10 in endochondral bone formation in mice: anabolic effect via the bone morphogenetic protein/Smad pathway (2013) Arthritis Rheum., 65 (12), pp. 3153-3164; van Meegeren, M.E., Roosendaal, G., Coeleveld, K., Nieuwenhuizen, L., Mastbergen, S.C., Lafeber, F.P., A single intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice (2013) Br. J. Haematol., 160 (4), pp. 515-520; Gordon, K.J., Blobe, G.C., Role of transforming growth factor-beta superfamily signaling pathways in human disease (2008) Biochim. Biophys. Acta, 1782 (4), pp. 197-228; Janssens, K., ten Dijke, P., Janssens, S., Van Hul, W., Transforming growth factor-beta1 to the bone (2005) Endocr. Rev., 26 (6), pp. 743-774; Zhen, G., Wen, C., Jia, X., Li, Y., Crane, J.L., Mears, S.C., Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis (2013) Nat. Med., 19 (6), pp. 704-712; Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation (2009) Nat. Med., 15 (7), pp. 757-765; Nagase, H., Kumakura, S., Shimada, K., Establishment of a novel objective and quantitative method to assess pain-related behavior in monosodium iodoacetate-induced osteoarthritis in rat knee (2012) J. Pharmacol. Toxicol. Methods, 65 (1), pp. 29-36; Ishikawa, G., Nagakura, Y., Takeshita, N., Shimizu, Y., Efficacy of drugs with different mechanisms of action in relieving spontaneous pain at rest and during movement in a rat model of osteoarthritis (2014) Eur. J Pharmacol., 738, pp. 111-117; Al-Saffar, F.J.G.S., Fakurazi, S., Yaakub, H., Lip, M., Chondroprotective effect of Zerumbone on Monosodium Iodoacetate induced osteoarthritis in rats (2010) Journal of Applied Sciences, 10 (4), pp. 248-260; Vogler, G.A., Suckow, M.A., Weisbroth, S., Franklin, C.L., Anesthesia and Analgesia in the Laboratory Rat (2006), pp. 627-695. , Elsevier Academic Press New York, USA; Pritzker, K.P., Gay, S., Jimenez, S.A., Ostergaard, K., Pelletier, J.P., Revell, P.A., Osteoarthritis cartilage histopathology: grading and staging (2006) Osteoarthr. Cartil., 14 (1), pp. 13-29; Pavelka, K., Gatterova, J., Olejarova, M., Machacek, S., Giacovelli, G., Rovati, L.C., Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study (2002) Arch. Intern. Med., 162 (18), pp. 2113-2123; McAlindon, T.E., LaValley, M.P., Felson, D.T., Efficacy of glucosamine and chondroitin for treatment of osteoarthritis (2000) JAMA, 284 (10), p. 1241; Kanzaki, N., Ono, Y., Shibata, H., Moritani, T., Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study (2015) Clin. Interv. Aging, 10, pp. 1743-1753; Terencio, M.C., Ferrandiz, M.L., Carceller, M.C., Ruhi, R., Dalmau, P., Verges, J., Chondroprotective effects of the combination chondroitin sulfate-glucosamine in a model of osteoarthritis induced by anterior cruciate ligament transection in ovariectomised rats (2016) Biomed. Pharmacother., 79, pp. 120-128; Rojas-Ortega, M., Cruz, R., Vega-Lopez, M.A., Cabrera-Gonzalez, M., Hernandez-Hernandez, J.M., Lavalle-Montalvo, C., Exercise modulates the expression of IL-1beta and IL-10 in the articular cartilage of normal and osteoarthritis-induced rats (2015) Pathol. Res. Pract., 211 (6), pp. 435-443; Muller, R.D., John, T., Kohl, B., Oberholzer, A., Gust, T., Hostmann, A., IL-10 overexpression differentially affects cartilage matrix gene expression in response to TNF-alpha in human articular chondrocytes in vitro (2008) Cytokine, 44 (3), pp. 377-385; Lacraz, S., Nicod, L.P., Chicheportiche, R., Welgus, H.G., Dayer, J.M., IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes (1995) J. Clin. Invest., 96 (5), pp. 2304-2310 | |
| dcterms.source | Scopus | |
| dc.identifier.doi | https://doi.org/10.1016/j.pathophys.2017.02.005 | |
| dc.identifier.doi | PubMed ID : | |
| dc.Affiliation | October University for modern sciences and Arts (MSA) |
